FDA Brief

Warning letters Drugs

FDA warning letter to

NSE Products, Inc. DBA Nu Skin Enterprises, Inc.

LowIssued Mar 2Posted Mar 10Center for Drug Evaluation and Research (CDER)

FDA warns NSE Products (Nu Skin) over incomplete drug listing data for AP-24 products and 61 inactivated listings.

What happened

FDA reviewed the firm’s electronic Drug Registration and Listing System (eDRLS) information, the FDA database for drug listings. FDA sent a December 10, 2025 deficiency letter, followed up, and on January 24, 2026 issued a data removal notice. It found AP-24 listings naming a manufacturing establishment that confirmed it had not made these drugs for more than five years with no end marketing date, and 61 drug listings that had not been updated or certified and were inactivated.

What FDA found

  1. The firm did not provide complete, accurate, up-to-date drug listing information as required.

    section 510(j) of the FD&C Act, 21 U.S.C. 360(j)
  2. The listings cited a manufacturing establishment that had not made the drugs for more than five years and had no end marketing date.

    21 CFR 207.57(b)(1)(iv); 21 CFR 207.49(a)(12)
  3. The firm did not review and update its drug listing information each June and December.

    section 510(j)(2) of the FD&C Act, 21 U.S.C. 360(j)(2); 21 CFR 207.57(b)
  4. Sixty-one drug listings were not updated or certified as required and were inactivated by FDA.

    21 CFR 207.57(b)
  5. Failure to provide drug listing information as required is prohibited.

    section 301(p) of the FD&C Act, 21 U.S.C. 331(p)

What FDA wants

FDA asks the company to update the listing information to current status or add end marketing dates for discontinued drugs, and to respond in writing within 15 working days with corrective steps and documentation.

Who should pay attention

  • drug companies that submit eDRLS listing data
  • contract manufacturers named in drug listings
  • sellers and distributors of listed drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  3. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  4. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk